NEWS・COLUMN
We send the latest information from SMC Laboratories.
Introduction of MAFLD criteria and the disease model
Today, we would like to introduce metabolic dysfunction-associated fatty liver disease (MAFLD), a new concept in the study of fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of fatty liver disease in the absence of any known causes of steatosis. The number of NAFLD cases are growing worldwide due…
The effect of the gut-liver axis dysfunction in liver disease
Today, I would like to introduce the relationship between Nonalcoholic steatohepatitis (NASH) and the gut. Factors contributing to the progression of the NASH include oxidative stress, lipotoxicity, and mitochondrial dysfunction, and recently much attention has been focused on gut-liver axis dysfunction. The gut and the liver are connected by a blood vessel called…
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), and today we would like to share SMC's thoughts on the development of a medicine for the treatment of Alzheimer's disease. There are currently five FDA-approved drugs for Alzheimer's disease (Donepezil, Rivastigmine, Galantamine, Memantine, and Aducanumab). These treatments can be divided into…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints used in the development of drug candidates for NASH, and the role it plays in our proprietary STAM™ model. But, first, what is NAS and how does it relate to the study of NASH?…
September is World Alzheimer’s Month!
In recognition of September 21st being World Alzheimer’s Day, why don’t we deepen our understanding of Alzheimer's disease? In 1994, the “Alzheimer's Disease International” (ADI), in collaboration with the World Health Organization (WHO), established September 21st as “World Alzheimer's Day” to raise awareness for people who suffer from dementia. In addition to this, September…
July 28th is World Hepatitis Day!
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help everyone around the globe have a deeper understanding of hepatitis, so please read on if you would like to learn more. In 2010, the World Health Organization (WHO) designated July 28th as…
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis (NASH) model called STAMTM (Ikewaki et al., bioRxiv, 2021). In this study, the authors evaluated how the single or combined consumption of two beta-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the…
Introduction of the paper using our UUO model
We would like to introduce a paper published by our client using Chronic kidney disease model. In this paper, the authors showed improvement of the disease state and analyzed the mechanism of UUO-induced kidney fibrosis model by histological analysis and gene expression analysis after the administration of compounds. About the UUO…
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. For…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH. However, no therapeutic medications for NASH have yet been launched. One of the reasons is the lack of animal models that can completely reproduce the pathology of NASH as seen in humans due to the…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers. Hepatitis B and C, alcohol, and diabetes are known to cause HCC, but NAFLD/NASH has been…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Marvel's press release. Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash | MARVEL Biotechnology